Impressive Phase III Results From RESONATE In CLL

Prof Peter Hillmen from Leeds Teaching Hospital, Leeds, UK, gives an update on the Phase III results from the RESONATE study in 391 patients with relapsed refractory chronic lymphoid leukemia (CLL).  Prof Hillmen outlines the progression-free and overall survival results which showed the significant benefits of ibrutinib over ofatumumab.  He comments on single- vs. combination therapy with ibrutinib in CLL.

Year of Production:
Running Time:
Color/Sound:

2014
03:12
Color/Sound

Comments are closed.